Pfizer
Trade Pfizer 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About PFE
Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.
PFE Key Statistics
Stock Snapshot
Pfizer(PFE) stock is priced at $25.90, giving the company a market capitalization of 147.23B. It carries a P/E multiple of 14.76 and pays a dividend yield of 6.8%.
As of 2025-12-11, Pfizer(PFE) stock has fluctuated between $25.71 and $26.04. The current price stands at $25.90, placing the stock +0.7% above today's low and -0.6% off the high.
Pfizer(PFE) shares are trading with a volume of 12.82M, against a daily average of 42.45M.
In the last year, Pfizer(PFE) shares hit a 52-week high of $27.69 and a 52-week low of $20.92.
In the last year, Pfizer(PFE) shares hit a 52-week high of $27.69 and a 52-week low of $20.92.
PFE News
Pfizer Inc. recently entered an exclusive global collaboration and license agreement with YaoPharma for YP05002, an oral GLP-1 receptor agonist in Phase 1 for c...
Pfizer (PFE) closed at $27.41 in the latest trading session, marking a +1.59% move from the prior day. The stock's change was more than the S&P 500's daily gain...
Pfizer Inc. (NYSE:PFE) on Wednesday shared detailed results from the Phase 3 HER2CLIMB-05 trial of Tukysa (tucatinib) as part of an investigational first-line m...
Analyst ratings
57%
of 28 ratingsMore PFE News
Pfizer PFE announced that it is in-licensing exclusive global rights to develop, manufacture and commercialize YP05002, an oral small molecule GLP-1 receptor ag...
Johnson & Johnson JNJ and Pfizer PFE are both healthcare leaders with large drug portfolios and diversified revenue streams, making them direct peers in the blu...
HSBC analyst Rajesh Kumar raised the firm’s price target on Pfizer (PFE) to $29 from $28 and keeps a Buy rating on the shares as part of a 2026 outlook for the...
Key Points Pfizer is one of the world's largest drugmakers. It has long managed to produce new blockbuster drugs to replace drugs losing patent protection. I...
Biotech and Pharma Pfizer Turns to China for Trial Weight Loss Drug. Congress Is Worried About Chinese Biotechs. In this article PFE REGN AZN NOVO.B LLY Pfizer...
Leerink analyst David Risinger notes that Pfizer (PFE) disclosed on December 9, 2025, that it entered into an exclusive global collaboration and license agreeme...
Pfizer (PFE) just put fresh data behind one of its more interesting pipeline assets, with Phase 3 results showing HYMPAVZI improved bleeding outcomes for hemoph...